{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:06:49Z","timestamp":1789142809374,"version":"build-2803163510"},"reference-count":79,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although rifampin drug\u2013drug interaction (DDI) studies are routinely conducted, there have been instances of liver function test (LFT) elevations, warranting further evaluation. A literature review was conducted to identify studies in which combination with rifampin resulted in hepatic events and evaluate any similarities. Over 600 abstracts and manuscripts describing rifampin DDI studies were first evaluated, of which 30 clinical studies reported LFT elevations. Out of these, 11 studies included ritonavir in combination with other drug(s) in the rifampin DDI study. The number of subjects that were discontinued from treatment on these studies ranged from 0 to 71 (0\u2013100% of subjects in each study). The number of subjects hospitalized for adverse events in these studies ranged from 0 to 41 (0\u201383.67% of subjects in each study). LFT elevations in greater than 50% of subjects were noted during the concomitant administration of rifampin with ritonavir\u2010boosted protease inhibitors and with lorlatinib; with labeled contraindication due to observed hepatotoxicity related safety findings only for saquinavir\/ritonavir and lorlatinib. In the lorlatinib and ritonavir DDI studies, considerable LFT elevations were observed rapidly, typically within 24\u201372\u00a0h following co\u2010administration. A possible sequence effect has been speculated, where rifampin induction prior to administration of the combination may be associated with increased severity of the LFT elevations. The potential role of rifampin in the metabolic activation of certain drugs into metabolites with hepatic effects needs to be taken into consideration when conducting rifampin DDI studies, particularly those for which the metabolic profiles are not fully elucidated.<\/jats:p>","DOI":"10.1111\/cts.13281","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T08:20:14Z","timestamp":1650961214000},"page":"1561-1580","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A literature review of liver function test elevations in rifampin <scp>drug\u2013drug<\/scp> interaction studies"],"prefix":"10.1111","volume":"15","author":[{"given":"Sherry M.","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdi K.","family":"Pithavala","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Global Product Development Pfizer Inc.  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoli","family":"Vourvahis","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Global Product Development Pfizer Inc.  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5998-7765","authenticated-orcid":false,"given":"Joseph","family":"Chen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Global Product Development Pfizer Inc.  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Rifampin Capsules USPU.S. Food & Drug Administration website. 2004. Accessed April 25 2022. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2004\/50429s083lbl.pdf"},{"key":"e_1_2_7_3_1","first-page":"263","article-title":"Basic review of the cytochrome P450 system","volume":"4","author":"McDonnell AM","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342090-00003"},{"key":"e_1_2_7_5_1","article-title":"Rifamycins (Rifampin, rifabutin, rifapentine)","author":"Drew RH","year":"2020","journal-title":"UpToDate."},{"key":"e_1_2_7_6_1","unstructured":"U.S. Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases Division of AIDSDivision of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1. Accessed April 25 2022.https:\/\/rsc.niaid.nih.gov\/sites\/default\/files\/daidsgradingcorrectedv21.pdf"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01198-9"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318189a7df"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282faa71e"},{"key":"e_1_2_7_10_1","unstructured":"Invirase (saquinavir mesylate) Capsules and TabletsU.S. Food & Drug Administration website. October 2010. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020628s033 021785s010lbl.pdf"},{"key":"e_1_2_7_11_1","unstructured":"Lorbrena (lorlatinib) TabletsU.S. Food & Drug Administration website. March 2021. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210868s004lbl.pdf"},{"key":"e_1_2_7_12_1","unstructured":"Crixivan (indinavir sulfate) CapsulesU.S Food & Administration website. November 2010. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/020685s073lbl.pdf"},{"key":"e_1_2_7_13_1","unstructured":"Kaletra (lopinavir and ritonavir)U.S. Food & Drug Administration website. November 2016. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021251s052_021906s046lbl.pdf"},{"key":"e_1_2_7_14_1","unstructured":"Prezista (duranavir)U.S. Food & Drug Administration website. December 2011. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021976s021lbl.pdf"},{"key":"e_1_2_7_15_1","unstructured":"Reyataz (atazanavir) CapsulesU.S Food & Administration website. February 2011. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/021567Orig1s025.pdf"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128274"},{"key":"e_1_2_7_17_1","unstructured":"Norvir (ritonavir)U.S. Food & Drug Administration website. June 2017. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209512lbl.pdf"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00341-07"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-5174.2009.00017.x"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01598-10"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/425610"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfq009"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab097"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1191\/096032700674230830"},{"key":"e_1_2_7_25_1","first-page":"1235","article-title":"Protective effect of N\u2010acetylcysteine on antituberculosis drug\u2010induced hepatotoxicity","volume":"22","author":"Baniasadi S","year":"2010","journal-title":"Meta Liv Dis"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.50.2.213"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2011.0247"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz557"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.021"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00461-06"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm484"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.680-684.2005"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz522"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03651-7"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1086\/422724"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1086\/422645"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-8-200210150-00007"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.495"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008321790"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.5.1553-1560.2004"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2014.06.006"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.6.2112"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044793"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-03392-5"},{"key":"e_1_2_7_45_1","first-page":"256","article-title":"Slow N\u2010acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin\u2010induced hepatotoxicity","volume":"4","author":"Ohno M","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2013.08.006"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702004000300004"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3181642257"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.40"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0157-9"},{"key":"e_1_2_7_51_1","unstructured":"Eliquis (apixaban) TabletsU.S. Food & Drug Administration website. December 2012. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202155s000lbl.pdf"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03545.x"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.08.012"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.102"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3182423478"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.038646"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-17"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90147-3"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00526-07"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12671"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.249"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1086\/314703"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0040296"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1997.tb00144.x"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.94"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02256.x"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70051-2"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009359524"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318183a425"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.11.012"},{"key":"e_1_2_7_71_1","unstructured":"Sustiva (efavirenz) Capsules and TabletsU.S. Food & Drug Administration website. February 2002. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/21360lbl.pdf"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.12.013"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1086\/320998"},{"key":"e_1_2_7_74_1","unstructured":"Viread (tenofovir disoproxil fumarate) TabletsU.S. Food & Drug Administration website. April 2019. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021356s058022577s014lbl.pdf"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305020-00023"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj060428"},{"key":"e_1_2_7_77_1","unstructured":"Zydelig (idelalisib) TabletsU.S. Food & Drug Administration website. July 2014. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205858lbl.pdf"},{"key":"e_1_2_7_78_1","unstructured":"Darunavir FDA NDA 21976 Clinical Pharmacology ReviewU.S. Food & Drug Administration website. June 2006. Accessed April 25 2022.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021976s000_Sprycel_ClinPharmR.pdf"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.119.087007"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03133.x"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13281","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13281","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13281","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T19:17:38Z","timestamp":1694891858000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1111\/cts.13281"],"URL":"https:\/\/doi.org\/10.1111\/cts.13281","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"2021-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}